FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2569722285> ?p ?o ?g. }

• W2569722285 endingPage "S701" @default.
• W2569722285 startingPage "S700" @default.
• W2569722285 abstract "We conducted a retrospective study to investigate the outcome and prognostic factors of patients with relapsed SCLC who receive second or third line chemotherapy with paclitaxel plus gemcitabine, a regimen that is used in our institution since a phase II trial in 2001. We reviewed the medical records of patients with SCLC who received paclitaxel plus gemcitabine in a ten-year period, since 2005 from 2015. Overall survival (OS) from the initiation of this regimen was evaluated, plus characteristics of these patients. Patients diagnosed of SCLC were selected from our lung cancer database, and compared with our Pharmacy Department database. We selected all patients with relapsed SCLC that received therapy with paclitaxel plus gemcitabine (PG) at any moment of the disease. The median age of the cohort was 58 years (43–81 years). There were 69 males (83.2%) and 14 females (16.8%). 72 patients (86.7%) had a previous history of smoking. ECOG PS at relapse was 0 in 3 (3.6%), 1 in 70 (84.3%), and 2 in 10 (12.1%) patients. Fifty patients (60.2%) had extensive disease at baseline diagnosis, and the remaining 33 (38.8%) had limited disease. All patients were exposed previously to etoposide and platinum. The platinum used was cisplatin in 52 patients (60.3%) and carboplatin in 30 patients (38.7%). Previous radiation at local tumor site was received by 38 patients (45.8%). The response was evaluated in 78 patients. The response post-2 months of PG was complete response in 2 patients (2.5%), partial response in 29 (37.1%), stable disease in 24 (30.7%), and progressive disease in 23 patients (30.6%). The median number of cycles of PG received was 8 (2-28) cycles. Toxicity related cessation of treatment was required in 12 patients (14.4%). The reason for stoppage was Grade 3–4 toxicities in 8 patients (9.6%) and deterioration in PS in 4 patients (4.8%) The median PFS was 148 days (95% CI: 30–173.5 days) while the median OS was 172 days (95% CI: 60–485 days). Paclitaxel plus gemcitabine it is a well-tolerated regimen in relapsed SCLC in the schedule we usually use (every 2 weeks). Unless this study is retrospective, we believe that this combination can be used nowadays in these patients, if there is no clinical trial available." @default.
• W2569722285 created "2017-01-13" @default.
• W2569722285 creator A5006862278 @default.
• W2569722285 creator A5025555281 @default.
• W2569722285 creator A5032621510 @default.
• W2569722285 creator A5038520067 @default.
• W2569722285 creator A5039382204 @default.
• W2569722285 creator A5050836369 @default.
• W2569722285 creator A5071254225 @default.
• W2569722285 creator A5082747316 @default.
• W2569722285 creator A5088315344 @default.
• W2569722285 creator A5089866416 @default.
• W2569722285 creator A5091344731 @default.
• W2569722285 creator A5091853126 @default.
• W2569722285 date "2017-01-01" @default.
• W2569722285 modified "2023-09-26" @default.
• W2569722285 title "P1.07-009 Outcomes of Patients with Relapsed Small-Cell Lung Cancer Treated with Paclitaxel plus Gemcitabine. 10 Year-Analysis" @default.
• W2569722285 doi "https://doi.org/10.1016/j.jtho.2016.11.920" @default.
• W2569722285 hasPublicationYear "2017" @default.
• W2569722285 type Work @default.
• W2569722285 sameAs 2569722285 @default.
• W2569722285 citedByCount "0" @default.
• W2569722285 crossrefType "journal-article" @default.
• W2569722285 hasAuthorship W2569722285A5006862278 @default.
• W2569722285 hasAuthorship W2569722285A5025555281 @default.
• W2569722285 hasAuthorship W2569722285A5032621510 @default.
• W2569722285 hasAuthorship W2569722285A5038520067 @default.
• W2569722285 hasAuthorship W2569722285A5039382204 @default.
• W2569722285 hasAuthorship W2569722285A5050836369 @default.
• W2569722285 hasAuthorship W2569722285A5071254225 @default.
• W2569722285 hasAuthorship W2569722285A5082747316 @default.
• W2569722285 hasAuthorship W2569722285A5088315344 @default.
• W2569722285 hasAuthorship W2569722285A5089866416 @default.
• W2569722285 hasAuthorship W2569722285A5091344731 @default.
• W2569722285 hasAuthorship W2569722285A5091853126 @default.
• W2569722285 hasBestOaLocation W25697222851 @default.
• W2569722285 hasConcept C126322002 @default.
• W2569722285 hasConcept C141071460 @default.
• W2569722285 hasConcept C143998085 @default.
• W2569722285 hasConcept C167135981 @default.
• W2569722285 hasConcept C2776256026 @default.
• W2569722285 hasConcept C2776694085 @default.
• W2569722285 hasConcept C2778119113 @default.
• W2569722285 hasConcept C2778239845 @default.
• W2569722285 hasConcept C2778336483 @default.
• W2569722285 hasConcept C2780258809 @default.
• W2569722285 hasConcept C2781413609 @default.
• W2569722285 hasConcept C2781451048 @default.
• W2569722285 hasConcept C71924100 @default.
• W2569722285 hasConceptScore W2569722285C126322002 @default.
• W2569722285 hasConceptScore W2569722285C141071460 @default.
• W2569722285 hasConceptScore W2569722285C143998085 @default.
• W2569722285 hasConceptScore W2569722285C167135981 @default.
• W2569722285 hasConceptScore W2569722285C2776256026 @default.
• W2569722285 hasConceptScore W2569722285C2776694085 @default.
• W2569722285 hasConceptScore W2569722285C2778119113 @default.
• W2569722285 hasConceptScore W2569722285C2778239845 @default.
• W2569722285 hasConceptScore W2569722285C2778336483 @default.
• W2569722285 hasConceptScore W2569722285C2780258809 @default.
• W2569722285 hasConceptScore W2569722285C2781413609 @default.
• W2569722285 hasConceptScore W2569722285C2781451048 @default.
• W2569722285 hasConceptScore W2569722285C71924100 @default.
• W2569722285 hasIssue "1" @default.
• W2569722285 hasLocation W25697222851 @default.
• W2569722285 hasOpenAccess W2569722285 @default.
• W2569722285 hasPrimaryLocation W25697222851 @default.
• W2569722285 hasRelatedWork W1969833561 @default.
• W2569722285 hasRelatedWork W2005371059 @default.
• W2569722285 hasRelatedWork W2031554341 @default.
• W2569722285 hasRelatedWork W2349270370 @default.
• W2569722285 hasRelatedWork W2381460883 @default.
• W2569722285 hasRelatedWork W2402121076 @default.
• W2569722285 hasRelatedWork W2461409983 @default.
• W2569722285 hasRelatedWork W2471989939 @default.
• W2569722285 hasRelatedWork W4254740740 @default.
• W2569722285 hasRelatedWork W2125019270 @default.
• W2569722285 hasVolume "12" @default.
• W2569722285 isParatext "false" @default.
• W2569722285 isRetracted "false" @default.
• W2569722285 magId "2569722285" @default.
• W2569722285 workType "article" @default.